Dual-functioning Targeted ADAM17 Blocker CD16 (TAB16) mediates selective ADAM17 inhibition in NK cells and engages overexpressed ADAM17 in tumor cells to induce cytotoxicity
Our ADAM17-engaging platform offers a unique approach for targeted ADAM17 inhibition to augment the anti-tumor function of endogenous and therapeutic NK cells.
Authors
- Robert Hullsiek
- Anders W. Matson (ORCID: https://orcid.org/0000-0001-8470-5822)
- Bruce Walcheck (ORCID: https://orcid.org/0000-0003-1933-3887)
- Geoffrey T. Hart (ORCID: https://orcid.org/0000-0003-0483-307X)
- Kate Dixon
- Martin Felices (ORCID: https://orcid.org/0000-0002-5945-0634)
- S Wang
- Yvette Soignier
- Ryan R. Friess
- Alexander J. Lenvik (ORCID: https://orcid.org/0000-0003-2870-917X)
- Jianming Wu
Institutions
- University of Minnesota (US)
- University of Minnesota Medical Center (US)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-01-30
- DOI
- https://doi.org/10.3389/fimmu.2026.1714022
- Citations
- 1
- Primary Topic
- Monoclonal and Polyclonal Antibodies Research
- Type
- article
- Field-Weighted Citation Impact
- 31.92
Funders
- National Institutes of Health
- National Cancer Institute